Beyond the imaging: Limitations of cellular uptake study in the evaluation of nanoparticles

Journal of Controlled Release

Volumn 164, Issue 2, 2012, Pages 170-176

  Gullotti, Emily ^a   Yeo, Yoon ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Bioactivity; Cellular uptake; Drug delivery; Drug release; Polymeric nanoparticles

Indexed keywords

BIOLOGICAL ENVIRONMENTS; CELL-PENETRATING PEPTIDE; CELLULAR UPTAKE; DRUG EFFECTS; DRUG RELEASE; DRUG RELEASE KINETICS; IMAGING LEVEL; INTRACELLULAR DELIVERY; PACLITAXEL; PHOSPHATE-BUFFERED SALINES; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMERIC NANOPARTICLES; RELEASE KINETICS; TWEEN 80;

BIOACTIVITY; COPOLYMERS; DRUG DELIVERY;

NANOPARTICLES;

CURCUMIN; NANOPARTICLE; PACLITAXEL; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; POLYSORBATE 80; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER CELL; CELL TRANSPORT; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; KINETICS; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; GENE PRODUCTS, TAT; HUMANS; LACTIC ACID; NANOPARTICLES; PACLITAXEL; POLYGLYCOLIC ACID;

EID: 84869508682     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.042     Document Type: Article

References (53)

1. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer - mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11 4 2000 265 283
2. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 16 2000 1295 1302
3. Y. Liu, L. Huang, and F. Liu Paclitaxel nanocrystals for overcoming multidrug resistance in cancer Mol. Pharmaceutics 7 3 2010 863 869
4. S. Yadav, L.E. van Vlerken, S.R. Little, and M.M. Amiji Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells Cancer Chemother. Pharmacol. 63 4 2009 711 722
5. Y. Wang, M. Saad, R.I. Pakunlu, J.J. Khandare, O.B. Garbuzenko, A.A. Vetcher, V.A. Soldatenkov, V.P. Pozharov, and T. Minko Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor Clin. Cancer Res. 14 11 2008 3607 3616
6. R.I. Pakunlu, Y. Wang, M. Saad, J.J. Khandare, V. Starovoytov, and T. Minko In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug J. Control. Release 114 2 2006 153 162
7. H. Thomas, and H.M. Coley Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein Cancer Control 10 2 2003 159 165
8. P. Kannan, S. Telu, S. Shukla, S.V. Ambudkar, V.W. Pike, C. Halldin, M.M. Gottesman, R.B. Innis, and M.D. Hall The specific P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2) ACS Chem. Neurosci. 2 2 2011 82 89
9. L.D. Curcio, D.Y. Bouffard, and K.J. Scanlon Oligonucleotides as modulators of cancer gene expression Pharmacol. Ther. 74 3 1997 317 332
10. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 9 2006 819 829
11. A.W. Tong, Y.A. Zhang, and J. Nemunaitis Small interfering RNA for experimental cancer therapy Curr. Opin. Mol. Ther. 7 2 2005 114 124
12. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 5 2002 631 651
13. D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, and A. Gabizon Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump Clin. Cancer Res. 6 5 2000 1949 1957
14. D. Kim, E.S. Lee, K.T. Oh, Z.G. Gao, and Y.H. Bae Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH Small 4 11 2008 2043 2050
15. M. Yokoyama Drug targeting with nano-sized carrier systems J. Artif. Organs 8 2 2005 77 84
16. S.K. Sahoo, and V. Labhasetwar Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention Mol. Pharmaceutics 2 5 2005 373 383
17. P. Xu, E. Gullotti, L. Tong, C.B. Highley, D.R. Errabelli, T. Hasan, J.-X. Cheng, D.S. Kohane, and Y. Yeo Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited Mol. Pharmaceutics 6 1 2009 190 201
18. M.D. Chavanpatil, Y. Patil, and J. Panyam Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux Int. J. Pharm. 320 1-2 2006 150 156
19. Y.S. Nam, J.Y. Park, S.H. Han, and I.S. Chang Intracellular drug delivery using poly(d,l-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1 Biotechnol. Lett. 24 24 2002 2093 2098
20. V.P. Torchilin Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers Adv. Drug Deliv. Rev. 60 4-5 2008 548 558
21. V.P. Torchilin, R. Rammohan, V. Weissig, and T.S. Levchenko TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors Proc. Natl. Acad. Sci. U. S. A. 98 15 2001 8786 8791
22. A.M. Koch, F. Reynolds, H.P. Merkle, R. Weissleder, and L. Josephson Transport of surface-modified nanoparticles through cell monolayers ChemBioChem 6 2 2005 337 345
23. C.C. Berry Intracellular delivery of nanoparticles via the HIV-1 tat peptide Nanomedicine-UK 3 3 2008 357 365
24. M. Alvarez, K. Paull, A. Monks, C. Hose, J.S. Lee, J. Weinstein, M. Grever, S. Bates, and T. Fojo Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J. Clin. Invest. 95 5 1995 2205 2214
25. J.S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A.T. Fojo, and S.E. Bates Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol. Pharmacol. 46 4 1994 627 638
26. D.A. Scudiero, A. Monks, and E.A. Sausville Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen J. Natl. Cancer Inst. 90 11 1998 862
27. L. Wu, A.M. Smythe, S.F. Stinson, L.A. Mullendore, A. Monks, D.A. Scudiero, K.D. Paull, A.D. Koutsoukos, L.V. Rubinstein, M.R. Boyd, and R.H. Shoemaker Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening Cancer Res. 52 11 1992 3029 3034
28. C. Wischke, and S.P. Schwendeman Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int. J. Pharm. 364 2 2008 298 327
29. E.C. Gryparis, M. Hatziapostolou, E. Papadimitriou, and K. Avgoustakis Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells Eur. J. Pharm. Biopharm. 67 1 2007 1 8
30. T. Yang, F.D. Cui, M.K. Choi, J.W. Cho, S.J. Chung, C.K. Shim, and D.D. Kim Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation Int. J. Pharm. 338 1-2 2007 317 326
31. C. Fonseca, S. Simões, and R. Gaspar Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity J. Control. Release 83 2 2002 273 286
32. L. Mu, and S.S. Feng A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS J. Control. Release 86 1 2003 33 48
33. B.K. Kang, S.K. Chon, S.H. Kim, S.Y. Jeong, M.S. Kim, S.H. Cho, H.B. Lee, and G. Khang Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo Int. J. Pharm. 286 1-2 2004 147 156
34. M.M. Yallapu, M. Jaggi, and S.C. Chauhan β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells Colloids Surf., B 79 2010 113 125
35. V.P. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging AAPS J. 9 2 2007 E128 E147
36. O.C. Farokhzad, S. Jon, A. Khademhosseini, T.-N.T. Tran, D.A. LaVan, and R. Langer Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells Cancer Res. 64 21 2004 7668 7672
37. E.S. Lee, Z.G. Gao, D. Kim, K. Park, I.C. Kwon, and Y.H. Bae Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance J. Control. Release 129 3 2008 228 236
38. H.L. Wong, R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian, and X.Y. Wu A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 317 3 2006 1372 1381
39. L. Zhang, J.M. Chan, F.X. Gu, J.-W. Rhee, A.Z. Wang, A.F. Radovic-Moreno, F. Alexis, R. Langer, and O.C. Farokhzad Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform ACS Nano 2 8 2008 1696 1702
40. Z. Poon, D. Chang, X. Zhao, and P.T. Hammond Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia ACS Nano 5 6 2011 4284 4292
41. Z.Q. Hou, C.M. Zhan, Q.W. Jiang, Q. Hu, L. Li, D. Chang, X.R. Yang, Y.X. Wang, Y. Li, S.F. Ye, L.Y. Xie, Y.F. Yi, and Q.Q. Zhang Both FA- and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution Nanoscale Res. Lett. 6 2011 563
42. P. Langcharoen, W. Punfa, S. Yodkeeree, W. Kasinrerk, C. Ampasavate, S. Anuchapreeda, and P. Limtrakul Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment Arch. Pharm. Res. 34 10 2011 1679 1689
43. C.K. Song, P. Balakrishnan, C.K. Shim, S.J. Chung, and D.D. Kim Enhanced in vitro cellular uptake of P-gp substrate by poloxamer-modified liposomes (PMLs) in MDR cancer cells J. Microencapsul. 28 6 2011 575 581
44. W.Q. Cao, J. Zhou, Y. Wang, and L. Zhu Synthesis and in vitro cancer cell targeting of folate-functionalized biodegradable amphiphilic dendrimer-like star polymers Biomacromolecules 11 12 2010 3680 3687
45. H.Y. Nam, S.M. Kwon, H. Chung, S.Y. Lee, S.H. Kwon, H. Jeon, Y. Kim, J.H. Park, J. Kim, S. Her, Y.K. Oh, I.C. Kwon, K. Kim, and S.Y. Jeong Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles J. Control. Release 135 3 2009 259 267
46. Y.Q. Shen, Y.H. Zhan, J.B. Tang, P.S. Xu, P.A. Johnson, M. Radosz, E.A. Van Kirk, and W.J. Murdoch Multifunctioning pH-responsive nanoparticles from hierarchical self-assembly of polymer brush for cancer drug delivery AICHE J. 54 11 2008 2979 2989
47. F. Esmaeili, M.H. Ghahremani, S.N. Ostad, F. Atyabi, M. Seyedabadi, M.R. Malekshahi, M. Amini, and R. Dinarvand Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate J. Drug Target. 16 5 2008 415 423
48. G. Mohajer, E.S. Lee, and Y.H. Bae Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells Pharm. Res. 24 9 2007 1618 1627
49. R.R. Sawant, and V.P. Torchilin Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo Int. J. Pharm. 374 1-2 2009 114 118
50. R.M. Sawant, J.P. Hurley, S. Salmaso, A. Kale, E. Tolcheva, T.S. Levchenko, and V.P. Torchilin SMART drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers Bioconjug. Chem. 17 4 2006 943 949
51. F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron, and V. Préat Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation J. Control. Release 133 1 2009 11 17
52. M. de Smet, E. Heijman, S. Langereis, N.M. Hijnen, and H. Grüll Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study J. Control. Release 150 1 2011 102 110
53. H. Chen, S. Kim, W. He, H. Wang, P.S. Low, K. Park, and J.X. Cheng Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging Langmuir 24 10 2008 5213 5217